Modulation of the expression of stat-1-dependent genes

Abstract

The present invention relates to decoy-oligonucleotides and antisense-oligonucleotides having the nucleic acid sequence according to SEQ ID NO: 1 to 43 as well as the use thereof as medicaments.

1 . A decoy-oligonucleotide comprising a nucleic acid strand exhibiting a sequence according to SEQ ID NO: 1 to 32 or 34 to 40. 
     
     
         2 . The decoy-oligonucleotide according to  claim 1 , wherein said decoy-oligonucleotide exhibits modified internucleotide bonds. 
     
     
         3 . A nucleic acid molecule having a sequence according to SEQ ID NO: 41 to 43. 
     
     
         4 . The nucleic acid molecule according to  claim 3 , wherein said nucleic acid molecule exhibits modified internucleotide bonds. 
     
     
         5 . A medicament comprising a decoy-oligonucleotide comprising a nucleic acid strand exhibiting a sequence according to SEQ ID NO: 1 to 32 or 34 to 40. 
     
     
         6 . A method for the prevention and/or therapy of a disease comprising administering to a patient in need thereof a decoy-oligonucleotide comprising a nucleic acid strand exhibiting a sequence according to SEQ ID NO: 1 to 32 or 34 to 40. 
     
     
         7 . The method of  claim 6 , wherein the disease comprises cardio-vascular complications, in particular of restenosis after percutaneous angioplasty and stenosis of venous bypasses, the transplant rejection, the graft versus host disease (GVHD), the ischemia/refusion related damage in the context of surgical interventions, of immunological hypersensitivity reactions (type I to V), auto-immune diseases, in particular diabetes mellitus, multiple sclerosis and rheumatoid arthritis, all forms of acute, sub-acute and chronic inflammatory diseases, in particular of the joints, in particular arthritis, of the respiratory organs, in particular bronchial asthma and chronic bronchitis, of the skin, in particular psoriasis and neurodermitis and of the gastro-intestinal tract, in particular ulcerative colitis and Chron's disease as well as of the septic shock. 
     
     
         8 . The method according to  claim 7 , wherein said decoy oligonucleotide exhibits modified internucleotide bonds. 
     
     
         9 . A method for the prevention and/or therapy of a disease comprising administering to a patient in need thereof a nucleic acid molecule having a sequence according to SEQ ID NO: 41 to 43. 
     
     
         10 . The method of  claim 9 , wherein the disease comprises cardio-vascular complications, in particular of restenosis after percutaneous angioplasty and stenosis of venous bypasses, the transplant rejection, the graft versus host disease (GVHD), the ischemia/refusion related damage in the context of surgical interventions, of immunological hypersensitivity reactions (type I to V), auto-immune diseases, in particular diabetes mellitus, multiple sclerosis and rheumatoid arthritis, all forms of acute, sub-acute and chronic inflammatory diseases, in particular of the joints, in particular arthritis, of the respiratory organs, in particular bronchial asthma and chronic bronchitis, of the skin, in particular psoriasis and neurodermitis and of the gastrointestinal tract, in particular ulcerative colitis and Chron's disease as well as of the septic shock. 
     
     
         11 . The method according to  claim 9 , wherein said nucleic acid molecule exhibits modified internucleotide bonds. 
     
     
         12 . The medicament according to  claim 5 , wherein said decoy oligonucleotide exhibits modified internucleotide bonds. 
     
     
         13 . A medicament comprising a nucleic acid molecule having a sequence according to SEQ ID NO: 41 to 43. 
     
     
         14 . The medicament according to  claim 13 , wherein said nucleic acid molecle exhibits modified internucleotide bonds.